Microbiota in drug resistance
Drug Resistance Updates · 2026
DOI: 10.1016/j.drup.2025.101311 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Ru Jia und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chinese Medicine & Integrative Medicine, Shanghai Geriatric Medical Center, Zhongshan Hospital, Fudan University, Shanghai 201104, Chin…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Antineoplastic Agents, Drug Resistance, Neoplasm, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 381 Literaturangaben. Gefördert von: Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Drug resistance, particularly those of anticancer drugs and antibiotics, poses a significant challenge in the treatment of diseases, severely compromising therapeutic efficacy and patient survival rates. In recent years, an increasing number of studies have highlighted the dual role of microbiota in either promoting or mitigating drug resistance. The microbiome exists in symbiosis with the host, playing a crucial role in maintaining physiological functions and regulating immune responses. However, dysbiosis within the microbial community may induce or exacerbate drug resistance. While antibiotic-mediated depletion of gut microbiota has been proposed as a strategy to combat resistance, it may paradoxically lead to increased resistance or even worsen treatment outcomes. In this review, we focus on anticancer and antimicrobial agents as representative examples to elucidate the association of microbiome and drug resistance. We provide a detailed discussion on the mechanisms by which microbial dysbiosis contributes to development of drug resistance. Additionally, we systematically summarize the latest advancements in microbiota-targeted therapeutic strategies aimed at overcoming resistance, including fecal microbiota transplantation, probiotics and prebiotics, and bacterial engineering approaches. Finally, we discuss the potential clinical applications of microbiota-modulating strategies for overcoming drug resistance and examine the current challenges and future research directions in this field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chinese Medicine & Integrative Medicine, Shanghai Geriatric Medical Center, Zhongshan Hospital, Fudan University, Shanghai 201104, China.
- School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
- Department of Urology Surgery, Shantou Central Hospital, Shantou 515041,China.
- The second clinical medical college, Zhejiang Chinese Medical University, Zhejiang 310053, China.
- Department of Cardiology, Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515000, China; School of Public Health, Shantou University, Shantou 515041, China.
- School of Public Health, Shantou University, Shantou 515041, China; Longhu People's Hospital, Shantou 515041, China.
Förderung
- Shanghai Municipal Health Commission
Zitieren
APA
Jia, R., Xiao, C. X., Zhang, Y. H., Hu, L. Y., Jun-Jun, Y., Zuo, R., Hu, Y. F., Xie, Y. H., Ma, X. L., Li, Q., & Hou, K. J. (2026). Microbiota in drug resistance. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101311
Vancouver
Jia R, Xiao CX, Zhang YH, Hu LY, Jun-Jun Y, Zuo R, et al. Microbiota in drug resistance. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2025.101311
BibTeX
@article{Jia2026,
author = {Jia, Ru and Xiao, Chuan-Xing and Zhang, Yong-Hai and Hu, Li-Yang and Jun-Jun, Y and Zuo, Rui and Hu, Yu-Fei and Xie, Yu-Hao and Ma, Xue-Lei and Li, Qi and Hou, Kai-Jian},
title = {Microbiota in drug resistance},
journal = {Drug Resistance Updates},
year = {2026},
doi = {10.1016/j.drup.2025.101311}
}
EUVIMED